The U.S. Food and Drug Administration granted accelerated approval to Otsuka’s sibeprenlimab (Voyxact), a humanized monoclonal antibody targeting APRIL, for adults with primary immunoglobulin A nephropathy (IgAN). The approval is based on interim results from the Phase III Visionary trial showing a substantial reduction in 24‑hour urine protein-to‑creatinine ratio at nine months and robust 12‑month durability in later analyses. Voyxact is delivered subcutaneously every four weeks and represents the first approved APRIL inhibitor for IgAN. Otsuka reported consistent treatment effects across prespecified subgroups and a safety profile comparable to placebo in the safety set. The approval opens a new commercial class in a disease with limited targeted options and several competing APRIL/BAFF‑axis programs in development.